# Next Generation Personalized Neuroblastoma Therapy

> **NCT02780128** · PHASE1 · TERMINATED · sponsor: **Yael P Mosse** · enrollment: 66 (actual)

## Conditions studied

- Neuroblastoma
- Cancer

## Interventions

- **PROCEDURE:** Biopsy
- **GENETIC:** Next Generation Sequencing
- **PROCEDURE:** Tumor Scans
- **PROCEDURE:** Bone marrow Tests
- **OTHER:** Physical Exam
- **OTHER:** Eye Exam
- **OTHER:** Labs
- **OTHER:** Pregnancy Test
- **BEHAVIORAL:** Interviews
- **OTHER:** ECG
- **OTHER:** Echocardiogram
- **DRUG:** Ribociclib
- **DRUG:** Ceritinib

## Key facts

- **NCT ID:** NCT02780128
- **Lead sponsor:** Yael P Mosse
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07
- **Primary completion:** 2022-08
- **Final completion:** 2022-08
- **Target enrollment:** 66 (ACTUAL)
- **Why stopped:** The goals of Part 1 (molecular screening) were met, but lack of therapies to match molecular aberrations made Part 2 (treatment) no longer feasible.
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02780128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02780128, "Next Generation Personalized Neuroblastoma Therapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02780128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*